Insider Transactions in Q4 2025 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,760
-3.45%
|
$67,680
$18.21 P/Share
|
|
Dec 18
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,760
+6.44%
|
$3,760
$1.86 P/Share
|
|
Nov 24
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
37,600
-42.49%
|
$639,200
$17.07 P/Share
|
|
Nov 24
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,600
+29.82%
|
$37,600
$1.86 P/Share
|
|
Nov 03
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,284
-14.32%
|
$75,408
$12.56 P/Share
|
|
Oct 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,130
-6.66%
|
$37,560
$12.8 P/Share
|
|
Oct 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+6.32%
|
-
|
|
Oct 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,087
-5.06%
|
$49,044
$12.8 P/Share
|
|
Oct 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,815
+3.72%
|
-
|
|
Oct 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,644
-6.68%
|
$43,728
$12.8 P/Share
|
|
Oct 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,532
+4.94%
|
-
|